Inflammation contributes to many chronic conditions. It is often associated with circulating
pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity …

Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as
promising therapeutic options for addressing Type‐2 diabetes, obesity, and related …

Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …

Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …

The twin epidemic of obesity and diabetes is a major crisis globally. Several epidemiologic
studies reveal the parallel escalation of obesity and diabetes. The term 'diabesity'expresses …

We are facing a global epidemic of obesity and type 2 diabetes. Weight loss, in the context of
obesity and type 2 diabetes, may improve glycaemic control and weight‐related …

The preproglucagon gene (Gcg) is expressed by specific enteroendocrine cells (L-cells) of
the intestinal mucosa, pancreatic islet α-cells, and a discrete set of neurons within the …

Exercise, obesity and type 2 diabetes are associated with elevated plasma concentrations of
interleukin-6 (IL-6). Glucagon-like peptide-1 (GLP-1) is a hormone that induces insulin …

The obesity pandemic is accompanied by increased risk of develo** metabolic syndrome
(MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic …